Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skye high on Japanese PhIII flutiform results

This article was originally published in Scrip

Executive Summary

SkyePharma and its Japanese partner Kyorin Pharmaceuticals have announced that asthma drug flutiform (fluticasone propionate plus formoterol fumarate) has met its primary endpoints in two Phase III studies in Japan. With a Japanese regulatory filing now likely before March 2013, SkyePharma's share price increased 11% to 77.74p when the news broke on 22 June.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017844

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel